Skip to main content

Select Drug Profiles

FDA Approvals
Trodelvy (Sacituzumab Govitecan-hziy) a New Targeted Therapy for Patients with Metastatic Triple-Negative Breast Cancer
Loretta Fala
Read More
FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Loretta Fala
Read More
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, January 1, 2019, Through June 15, 2020
Read More
Leukemia, Lymphoma, Oncology
Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Chase Doyle
Chase Doyle
Read More
Maintenance Avelumab New Standard of Care for Advanced Bladder Cancer
Phoebe Starr
Phoebe Starr
Read More
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Wayne Kuznar
Wayne Kuznar
Read More
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
Wayne Kuznar
Chase Doyle
Read More
Multiple Myeloma, Oncology
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
Chase Doyle
Read More
Breast Cancer, Oncology
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Chase Doyle
Wayne Kuznar
Read More
Breast Cancer, Oncology
No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer
Phoebe Starr
Phoebe Starr
Read More
Page 31 of 244
Results 301 - 310 of 2434